Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/jRCTs051180080
jRCTs051180080CompletedNot Applicable

Treatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese Patients (An open treatment trial of NMO with MMF)

Not provided0 sites10 target enrollmentStarted: December 12, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
10
Primary Endpoint
No clinical relapse
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Single Arm Study
Intervention Model
Single Assignment
Primary Purpose
Treatment Purpose
Masking
Open(masking Not Used)

Eligibility Criteria

Ages
20age old over to 80age old not (—)
Sex
All

Inclusion Criteria

  • •Stable Neuromyelitis Optica patients with EDSS score less than 7.0 who wish to participate in this study

Exclusion Criteria

  • •Patients with infection
  • •Patients with pregnancy or breast-feeding
  • •Patients who take any immunosuppressant other than steroid
  • •patients with severe liver or kidney dysfunction
  • •patients with a history of cancer within 5 years (including carcinoma in situ)
  • •In addition, patients judged inappropriate by the investigators

Outcomes

Primary Outcomes

No clinical relapse

Time Frame: 1 year after starting Mycophenolate mofetil

There is no clinical relapse with this combination therapy

Steroid dose halved

Time Frame: 1 year after starting Mycophenolate mofetil

Whether the steroid dose is halved according to the treatment protocol

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Not provided

Similar Trials

Completed
Not Applicable
Treatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese Patientseuromyelitis Optica
JPRN-UMIN000031135Kobe University Hospital9
Unknown
Phase 4
Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese PatientsNeuromyelitis Optica Spectrum DisordersMycophenolate MofetilEfficacy and Safety
NCT02809079Third Affiliated Hospital, Sun Yat-Sen University100
Completed
Phase 2
Treatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese Patients
JPRN-jRCTs051180080Sekiguchi Kenji9
Completed
Phase 3
Mycophenolate sodium (Myfortic) in the Treatment of Uveitis: a Pilot Study.inflammatory eye disease1002187710027665uveitis
NL-OMON30290Academisch Medisch Centrum24
Active, not recruiting
Not Applicable
Inflammation of the optic nerve and early treatment with prednisolone.
EUCTR2012-002628-34-DKThor Petersen